More positive CV outcomes data

Data from ongoing clinical trials continue to show positive effects on cardiovascular outcomes with newer glucose-lowering drugs.
Eli Lilly has reported that adding dulaglutide 1.5mg once-weekly to standard care in people with type 2 diabetes significantly reduced major adverse cardiovascular events (a composite endpoint of cardiovascular …

More details...

500 people with diabetes die prematurely every week

Diabetes UK has used the latest National Diabetes Audit (NDA) data to publicise the high level of premature mortality among people with diabetes in England and Wales (www.diabetes.org.uk).
The charity analysed data from 2015, which recorded 102 010 deaths in people included in the NDA that …

More details...

Banning energy drinks sales to children

The Government is seeking the public’s views on banning sales of energy drinks to children and young people. The plan is part of its strategy to halve childhood obesity by 2030.
More than two-thirds of 10- to 17-year-olds and a quarter of 6- to 9-year-olds consume …

More details...

Lorcaserin hits the headlines

Public faith that a solution to obesity can be found in medication received a boost with the enthusiastic response of lay media to the results of the CAMELLIA–TIMI 61 (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61) trial …

More details...

Large UK trials test aspirin and omega-3 fatty acids

The UK ASCEND Study Group recently reported large trials that addressed two thorny issues in its study population of 15,480 people with diabetes but no cardiovascular disease.
The balance of risk and benefit with aspirin in people with diabetes has lately been against primary prevention. This …

More details...

Diabetes toolkit for university students

Diabetes UK, the Juvenile Diabetes Research Foundation and NHS England have developed a toolkit for young people with type 1 diabetes who are attending university or college (http://uni.jdrf.org.uk). The toolkit includes advice on lifestyle, independent living and making the most of the resources available to …

More details...

Not all type 2 diabetes reversible by extreme weight loss

Pancreatic cells in people with type 2 diabetes may not recover the ability to produce sufficient insulin if they do not overcome ‘the stress of being surrounded by internal fat’, according to Professor Roy Taylor, joint lead investigator of the DiRECT trial.
 DiRECT showed that extreme …

More details...

Negative results clear empagliflozin and liraglutide, no cancer benefit with aspirin

Three analyses of large studies involving people with diabetes have all proved negative – with different implications.
Boerhinger Ingelheim has reported an analysis of pooled data from trials of its SGLT2 inhibitor empagliflozin involving over 12,000 patients to determine its impact on the risk of bone …

More details...

2nd generation antipsychotics reduce insulin sensitivity and cause weight gain in young people

Second generation antipsychotics are associated with clinically evident metabolic effects in young people after only 12 weeks, say US researchers (JAMA Psychiatry June 13, 2018. doi:10.1001/jamapsychiatry.2018.1088).
The study involved 144 young people aged 6 – 18 (mean 11) who were considered for treatment with an antipsychotic …

More details...

Diabetes and pancreatic cancer

‘Recent-onset diabetes is a manifestation of pancreatic cancer and long-standing diabetes is a risk factor for this malignancy’, say US investigators (Journal of the National Cancer Institute, djy090, https://doi.org/10.1093/jnci/djy090).
Their cohort study included 49,000 people of African American or Latin ethnic origin who did not have …

More details...

Web design and marketing agency Leamington Spa